At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Mifepristone 600-mg/day or placebo for a weekdrug
Likely dose
Mifepristone 600-mg/day or placebo for a week 32.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study on the Safety and Efficacy of Mifepristone for the Prevention of Relapses of Alcohol Drinking
In Brief
A Phase 2 clinical trial evaluating Mifepristone 600-mg/day or placebo for a week for Alcohol Use Disorders (AUD). Completed, enrolled 32 participants across 1 site.
Detailed Summary
The goal of this study is to determine if, under stress, alcohol drinking is reduced using mifepristone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorders (AUD)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionDec 2021
TodayJul 2026
First PostedSep 18, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 21, 2021
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 11.8 years ago
Interventions
Mifepristone 600-mg/day or placebo for a weekdrug
600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine